Umbilical cord blood transplantation: the first 25 years and beyond

Karen K. Ballen, Eliane Gluckman, Hal Broxmeyer

Research output: Contribution to journalArticle

345 Citations (Scopus)

Abstract

Umbilical cord blood is an alternative hematopoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation. Initially, umbilical cord blood transplantation was limited to children, given the low cell dose infused. Both related and unrelated cord blood transplants have been performed with high rates of success for a variety of hematologic disorders and metabolic storage diseases in the pediatric setting. The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilical cord blood units and improved supportive care techniques. Cord blood expansion trials have recently shown improvement in time to engraftment. Umbilical cord blood is being compared with other graft sources in both retrospective and prospective trials. The growth of the field over the last 25 years and the plans for future exploration are discussed.

Original languageEnglish
Pages (from-to)491-498
Number of pages8
JournalBlood
Volume122
Issue number4
DOIs
StatePublished - Jul 25 2013

Fingerprint

Fetal Blood
Blood
Transplantation
Transplants
Pediatrics
Hematologic Diseases
Metabolic Diseases
Cell Transplantation
HLA Antigens
Hematopoietic Stem Cells
Stem cells
Grafts
Growth

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Umbilical cord blood transplantation : the first 25 years and beyond. / Ballen, Karen K.; Gluckman, Eliane; Broxmeyer, Hal.

In: Blood, Vol. 122, No. 4, 25.07.2013, p. 491-498.

Research output: Contribution to journalArticle

Ballen, Karen K. ; Gluckman, Eliane ; Broxmeyer, Hal. / Umbilical cord blood transplantation : the first 25 years and beyond. In: Blood. 2013 ; Vol. 122, No. 4. pp. 491-498.
@article{05cd573a0a984a3799a8a2491802ea0b,
title = "Umbilical cord blood transplantation: the first 25 years and beyond",
abstract = "Umbilical cord blood is an alternative hematopoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation. Initially, umbilical cord blood transplantation was limited to children, given the low cell dose infused. Both related and unrelated cord blood transplants have been performed with high rates of success for a variety of hematologic disorders and metabolic storage diseases in the pediatric setting. The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilical cord blood units and improved supportive care techniques. Cord blood expansion trials have recently shown improvement in time to engraftment. Umbilical cord blood is being compared with other graft sources in both retrospective and prospective trials. The growth of the field over the last 25 years and the plans for future exploration are discussed.",
author = "Ballen, {Karen K.} and Eliane Gluckman and Hal Broxmeyer",
year = "2013",
month = "7",
day = "25",
doi = "10.1182/blood-2013-02-453175",
language = "English",
volume = "122",
pages = "491--498",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Umbilical cord blood transplantation

T2 - the first 25 years and beyond

AU - Ballen, Karen K.

AU - Gluckman, Eliane

AU - Broxmeyer, Hal

PY - 2013/7/25

Y1 - 2013/7/25

N2 - Umbilical cord blood is an alternative hematopoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation. Initially, umbilical cord blood transplantation was limited to children, given the low cell dose infused. Both related and unrelated cord blood transplants have been performed with high rates of success for a variety of hematologic disorders and metabolic storage diseases in the pediatric setting. The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilical cord blood units and improved supportive care techniques. Cord blood expansion trials have recently shown improvement in time to engraftment. Umbilical cord blood is being compared with other graft sources in both retrospective and prospective trials. The growth of the field over the last 25 years and the plans for future exploration are discussed.

AB - Umbilical cord blood is an alternative hematopoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation. Initially, umbilical cord blood transplantation was limited to children, given the low cell dose infused. Both related and unrelated cord blood transplants have been performed with high rates of success for a variety of hematologic disorders and metabolic storage diseases in the pediatric setting. The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilical cord blood units and improved supportive care techniques. Cord blood expansion trials have recently shown improvement in time to engraftment. Umbilical cord blood is being compared with other graft sources in both retrospective and prospective trials. The growth of the field over the last 25 years and the plans for future exploration are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84885934963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885934963&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-02-453175

DO - 10.1182/blood-2013-02-453175

M3 - Article

C2 - 23673863

AN - SCOPUS:84885934963

VL - 122

SP - 491

EP - 498

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -